Hennion & Walsh Asset Management Inc. Buys 413 Shares of United Therapeutics Co. (NASDAQ:UTHR)

Hennion & Walsh Asset Management Inc. lifted its stake in United Therapeutics Co. (NASDAQ:UTHR) by 14.4% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 3,291 shares of the biotechnology company’s stock after acquiring an additional 413 shares during the period. Hennion & Walsh Asset Management Inc.’s holdings in United Therapeutics were worth $756,000 at the end of the most recent quarter.

Other hedge funds have also recently made changes to their positions in the company. International Assets Investment Management LLC lifted its position in shares of United Therapeutics by 13,769.2% during the fourth quarter. International Assets Investment Management LLC now owns 9,015 shares of the biotechnology company’s stock valued at $1,982,000 after buying an additional 8,950 shares during the last quarter. DekaBank Deutsche Girozentrale boosted its stake in United Therapeutics by 54.4% in the fourth quarter. DekaBank Deutsche Girozentrale now owns 94,643 shares of the biotechnology company’s stock valued at $20,617,000 after acquiring an additional 33,338 shares in the last quarter. Nordea Investment Management AB grew its holdings in United Therapeutics by 155.2% in the fourth quarter. Nordea Investment Management AB now owns 38,698 shares of the biotechnology company’s stock worth $8,427,000 after purchasing an additional 23,532 shares during the last quarter. BNP Paribas Financial Markets increased its position in shares of United Therapeutics by 90.3% during the fourth quarter. BNP Paribas Financial Markets now owns 55,481 shares of the biotechnology company’s stock worth $12,200,000 after purchasing an additional 26,325 shares in the last quarter. Finally, Duality Advisers LP lifted its holdings in shares of United Therapeutics by 56.1% during the 4th quarter. Duality Advisers LP now owns 15,642 shares of the biotechnology company’s stock valued at $3,440,000 after purchasing an additional 5,622 shares during the last quarter. 94.08% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several brokerages recently weighed in on UTHR. StockNews.com downgraded United Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Thursday, June 20th. Wells Fargo & Company increased their price objective on shares of United Therapeutics from $325.00 to $350.00 and gave the company an “overweight” rating in a research report on Wednesday, June 12th. Oppenheimer boosted their target price on shares of United Therapeutics from $375.00 to $400.00 and gave the stock an “outperform” rating in a research report on Thursday, May 2nd. HC Wainwright restated a “buy” rating and set a $300.00 price target on shares of United Therapeutics in a research note on Thursday, May 2nd. Finally, The Goldman Sachs Group boosted their price objective on shares of United Therapeutics from $218.00 to $240.00 and gave the company a “neutral” rating in a report on Friday, May 3rd. One research analyst has rated the stock with a hold rating and ten have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $312.22.

United Therapeutics Stock Performance

NASDAQ UTHR opened at $319.01 on Tuesday. United Therapeutics Co. has a fifty-two week low of $208.62 and a fifty-two week high of $325.00. The company has a debt-to-equity ratio of 0.04, a quick ratio of 3.64 and a current ratio of 3.77. The firm has a market capitalization of $14.15 billion, a P/E ratio of 15.08, a PEG ratio of 1.40 and a beta of 0.55. The stock has a 50-day simple moving average of $276.47 and a two-hundred day simple moving average of $244.40.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings results on Wednesday, May 1st. The biotechnology company reported $6.17 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.63 by $0.54. The company had revenue of $677.70 million during the quarter, compared to the consensus estimate of $620.31 million. United Therapeutics had a return on equity of 18.72% and a net margin of 42.05%. United Therapeutics’s revenue for the quarter was up 33.7% on a year-over-year basis. During the same period in the previous year, the company posted $4.86 earnings per share. On average, equities analysts forecast that United Therapeutics Co. will post 24.73 earnings per share for the current year.

Insider Buying and Selling

In other United Therapeutics news, Director Christopher Causey sold 2,240 shares of the company’s stock in a transaction dated Friday, May 3rd. The shares were sold at an average price of $259.91, for a total value of $582,198.40. Following the completion of the transaction, the director now owns 4,185 shares in the company, valued at $1,087,723.35. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. In related news, Director Christopher Causey sold 2,240 shares of United Therapeutics stock in a transaction dated Friday, May 3rd. The stock was sold at an average price of $259.91, for a total value of $582,198.40. Following the completion of the transaction, the director now owns 4,185 shares in the company, valued at approximately $1,087,723.35. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Martine A. Rothblatt sold 3,600 shares of the stock in a transaction that occurred on Thursday, June 27th. The stock was sold at an average price of $316.62, for a total value of $1,139,832.00. Following the transaction, the chief executive officer now owns 130 shares in the company, valued at approximately $41,160.60. The disclosure for this sale can be found here. Over the last three months, insiders have sold 126,344 shares of company stock valued at $32,426,462. Corporate insiders own 12.50% of the company’s stock.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.